St. Jude Medical
This article was originally published in The Gray Sheet
U.S. clinical study begins of the Trilogy pacemaker in conjunction with a specially designed endocardial left ventricular pacing lead to treat atrial fibrillation and congestive heart failure. In the trial, which is part of a larger St. Jude program to investigate emerging indications for pacing therapy, "we aim to demonstrate that pacing the left ventricle...of the heart may have a beneficial effect on the arrhythmia itself and on several aspects of cardiac function," states lead investigator Aurelio Duran, MD, Orlando Heart Center, Florida
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.